BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance
Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals' CEO Michael Taylor about the company's cell-signaling technology, based on a clinical pipeline of kinase inhibitors. Taylor also explains the company's strategy of addressing drug resistance in cancer. By simultaneously blocking multiple cancer signaling mechanisms, Deciphera believes its therapies can control drug-resistant mutations while improving therapeutic potency, durability, and selectivity. Its pipeline includes three Phase I assets and a preclinical program.